Theravance Biopharma, Inc.
HealthcareNASDAQ:TBPH · NASDAQ Global Market
+$0.15 today
Vol 0.23M · Avg 0.44M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$109.8M of revenue converted into $114.5M of net income for the selected period. Gross margin is 77.0% and net margin is 83.1%, showing how much revenue survives after costs and taxes. EPS is $2.20, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $107.5M +66.9% | $64.4M +12.1% | $57.4M +11.8% | $51.3M -7.2% | $55.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $5.5M | $0 -100.0% | $40.6M -35.9% | $63.4M -67.3% | $193.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $101.9M +58.4% | $64.4M +283.2% | $16.8M +239.5% | -$12.0M +91.3% | -$138.3M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 94.9% -5.1pp | 100.0% +70.7pp | 29.3% +52.7pp | -23.5% +226.7pp | -250.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $37.4M -0.6% | $37.6M -18.8% | $46.3M -33.9% | $70.1M -65.2% | $201.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $73.7M +6.5% | $69.2M -1.8% | $70.5M +5.0% | $67.1M -32.5% | $99.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $115.2M +3.5% | $111.3M +52.8% | $72.8M -8.9% | $79.9M -33.1% | $119.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $5.5M +52.6% | $3.6M +80.7% | $2.0M -34.1% | $3.0M -36.9% | $4.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | $137.2M +456.9% | -$38.5M +25.5% | -$51.6M +32.1% | -$76.1M +67.3% | -$232.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 127.7% +187.4pp | -59.7% +30.2pp | -89.9% +58.2pp | -148.2% +272.8pp | -420.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$13.2M +71.8% | -$46.9M +16.2% | -$56.0M +39.1% | -$92.0M +64.3% | -$257.8M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -12.3% +60.6pp | -72.9% +24.7pp | -97.6% +81.5pp | -179.1% +287.0pp | -466.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $4.9M -46.5% | $9.1M +6.7% | $8.5M +670.5% | $1.1M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $2.5M -3.3% | $2.5M +8.3% | $2.4M -63.1% | $6.4M -25.5% | $8.5M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $142.5M +6002.5% | $2.3M -65.5% | $6.8M +888.6% | -$858.0K +88.5% | -$7.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $129.2M +389.7% | -$44.6M +9.4% | -$49.3M +46.9% | -$92.8M +65.0% | -$265.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 120.3% +189.6pp | -69.3% +16.5pp | -85.8% +95.0pp | -180.8% +298.7pp | -479.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $23.4M +97.8% | $11.8M +99.3% | $5.9M +65722.2% | $9.0K +106.0% | -$151.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $105.9M +287.7% | -$56.4M -2.2% | -$55.2M -106.3% | $872.1M +537.3% | -$199.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | 98.5% +186.2pp | -87.6% +8.5pp | -96.1% -1794.7pp | 1698.5% +2059.1pp | -360.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $2 +282.6% | -$1 -15.0% | -$1 +20.6% | -$1 +56.1% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $2 +279.1% | -$1 -15.0% | -$1 +20.6% | -$1 +56.1% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $50.3M +3.0% | $48.8M -11.7% | $55.3M -24.9% | $73.6M +5.9% | $69.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $51.5M +5.4% | $48.8M -11.7% | $55.3M -24.9% | $73.6M +5.9% | $69.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Tyra Biosciences, Inc.
NASDAQ:TYRA
$1.61B
Vir Biotechnology, Inc.
NASDAQ:VIR
$1.45B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.42B
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUE
$1.19B
BlackRock Technology and Private Equity Term Trust
BTX
$1.05B
Geron Corporation
NASDAQ:GERN
$737.75M
Replimune Group, Inc.
NASDAQ:REPL
$733.24M
Valneva SE
NASDAQ:VALN
$507.78M
LENZ Therapeutics, Inc.
NASDAQ:LENZ
$212.27M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TBPH generate?
Theravance Biopharma, Inc. (TBPH) reported $107.46M of revenue in fiscal 2025.
Is TBPH profitable?
Theravance Biopharma, Inc. (TBPH) reported $105.89M of net income, with a net margin of 98.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.